$7.28
2.54% today
Nasdaq, Jul 28, 10:17 pm CET
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock price

$7.28
+0.98 15.56% 1M
-2.24 23.53% 6M
-0.76 9.45% YTD
-9.14 55.66% 1Y
-49.83 87.25% 3Y
-141.32 95.10% 5Y
-236.62 97.02% 10Y
-11.52 61.28% 20Y
Nasdaq, Closing price Mon, Jul 28 2025
-0.19 2.54%
ISIN
US6700021040
Symbol
NVAX
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$707.1m
Net debt
positive
Cash
$731.5m
Shares outstanding
162.0m
Valuation (TTM | estimate)
P/E
2.8 | 3.1
P/S
1.0 | 1.1
EV/Sales
0.6 | 0.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-40.0%
Return on Equity
30.1%
ROCE
48.6%
ROIC
149.6%
Debt/Equity
-3.0
Financials (TTM | estimate)
Revenue
$1.3b | $1.1b
EBITDA
$467.5m | $488.7m
EBIT
$422.8m | $483.4m
Net Income
$478.7m | $393.5m
Free Cash Flow
$-196.6m
Growth (TTM | estimate)
Revenue
25.9% | 55.4%
EBITDA
240.1% | 366.4%
EBIT
211.8% | 308.4%
Net Income
220.1% | 309.9%
Free Cash Flow
61.7%
Margin (TTM | estimate)
Gross
87.5%
EBITDA
37.3% | 46.1%
EBIT
33.7%
Net
38.1% | 37.1%
Free Cash Flow
-15.7%
More
EPS
$2.7
FCF per Share
$-1.2
Short interest
26.7%
Employees
952
Rev per Employee
$720.0k
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Novavax, Inc. forecast:

9x Buy
64%
3x Hold
21%
2x Sell
14%

Analyst Opinions

14 Analysts have issued a Novavax, Inc. forecast:

Buy
64%
Hold
21%
Sell
14%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,255 1,255
26% 26%
100%
- Direct Costs 157 157
57% 57%
12%
1,098 1,098
75% 75%
88%
- Selling and Administrative Expenses 289 289
32% 32%
23%
- Research and Development Expense 387 387
33% 33%
31%
468 468
240% 240%
37%
- Depreciation and Amortization 45 45
1% 1%
4%
EBIT (Operating Income) EBIT 423 423
212% 212%
34%
Net Profit 479 479
220% 220%
38%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
PRNewsWire
4 days ago
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts  GAITHERSBURG, Md. , July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX...
Positive
The Motley Fool
17 days ago
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.
Neutral
Seeking Alpha
about 2 months ago
Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Ruxandra Draghia-Akli - EVP and Head of Research & Development John Charles Jacobs Are we ready to go? Are we live?
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today